Objective： Her-2/neu protein overexpression has been demonstrated in lung adenocarcinoma. Its overexpression often indicates a poor prognosis and resistance to chemotherapeutic agents. The objectives of this paper is...Objective： Her-2/neu protein overexpression has been demonstrated in lung adenocarcinoma. Its overexpression often indicates a poor prognosis and resistance to chemotherapeutic agents. The objectives of this paper is to explore the effectiveness of double-stranded short inhibitory RNAs （siRNA） targeting Her-2/neu oncogene on the drug sensitivity of Her-2/neu-overexpressing lung adenocarcinoma cells. Methods： Lung adenocarcinoma cell line calu-3 was transfected with siRNAs formulated LipofectAMINE 2000, and Her-2/neu protein and P-gp were determined by flow cytometry （FCM）. The chemosensitivity of transfected cells to cisplatin （CDDP） was measured by MTT. Cell apoptosis detection kit （Annexin V method） was used to examine the drug induced apoptosis rate. Results： siRNA targeting Her-2/neu greatly reduced the cell surface expression of Her-2/neu protein and had no effect on P-gp. Consequently the inhibitory rate of CDDP in combination with siRNA targeting Her-2/neu was （67.1±2.3）%, while the inhibitory rates were （48.1±3.5）%, （46.3±5.9）% and （50.2±2.9）% in untreated control, empty vector and unrelated siRNA groups, respectively. The FCM results showed that the apoptosis rate of cells treated with CDDP combined with siRNAs-Her-2/neu was elevated when compared with unrelated siRNA group and empty vector group. Conclusion： Sequence specific siRNA targeting Her-2/neu was capable of enhancing the chemosensitivity of calu-3 cell to cisplatin.展开更多
OBJECTIVE Various studies examining the relationship be-tween HER-2 over-expression and the response to chemotherapy and clinical outcome in patients with osteosarcoma have yielded inconclusive results.The purpose of ...OBJECTIVE Various studies examining the relationship be-tween HER-2 over-expression and the response to chemotherapy and clinical outcome in patients with osteosarcoma have yielded inconclusive results.The purpose of the current study was to evaluate the relation of HER-2 status with the response to chemo-therapy and clinical outcome in osteosarcoma.METHODS We conducted a meta-analysis of 6 studies that evaluated the correlation between HER-2 status and histologic response to chemotherapy and 2-year survival.Data were syn-thesized in summary receiver operating characteristic curves and with summary likelihood ratios(LRs) and relative risk.RESULTS The quantitative synthesis showed that HER-2 status is not a prognostic factor for the response to chemotherapy.The positive LR was 1.27(95% conf idence interval,0.91～1.77),and the negative LR was 0.68(95% confidence interval,0.38～1.22).There was no significant between-study heterogeneity.HER2-positive status tended to be associated with a worse 2-year survival,but the overall results were not formally statistically signif icant.CONCLUSION HER-2 status is not associated with the histo-logic response to chemotherapy in patients with osteosarcoma,whereas HER-2 positive patients may be associated with decreased survival.展开更多
目的探讨用荧光原位杂交(fluorescent in situ hybridization,FISH)方法检测乳腺癌HER-2/neu基因表达的临床意义。方法应用FISH法对2008年1月至2008年7月在首都医科大学附属北京天坛医院就诊的33例女性新发乳腺癌患者进行HER-2/neu基因...目的探讨用荧光原位杂交(fluorescent in situ hybridization,FISH)方法检测乳腺癌HER-2/neu基因表达的临床意义。方法应用FISH法对2008年1月至2008年7月在首都医科大学附属北京天坛医院就诊的33例女性新发乳腺癌患者进行HER-2/neu基因检测,分析基因表达程度与临床病理特征之间的关系,比较基因和免疫组化(IHC)法蛋白表达的差别。结果33位受试者中HER-2/neu基因过表达率为39.4%,其过表达与肿瘤大小、绝经与否、临床分期之间差异无统计学意义(P>0.05)。该基因在有腋淋巴结转移组显著高于无淋巴结转移组(P<0.05),ER阴性组高于ER阳性组,差异有统计学意义(P<0.01)。PR阴性组与阳性组间差异无统计学意义。P53基因阳性组显著高于阴性组(P<0.05)。HER-2/neu基因过表达者11例为免疫组化HER-2蛋白强阳性病例;2例为中度阳性病例。结论FISH技术可稳定检测乳腺癌中HER-2/neu基因的表达程度,其过表达与绝经与否、肿瘤大小、临床分期无关,与腋淋巴结转移和P53基因表达成正相关,与ER呈密切负相关。HER-2蛋白高强度表达(3+)与基因扩增有极好的一致性,而中等强度表达(2+)必须进一步行FISH法基因检测。展开更多
基金This work was supported by the National Natural Science Foundation of China (No.30371624).
文摘Objective： Her-2/neu protein overexpression has been demonstrated in lung adenocarcinoma. Its overexpression often indicates a poor prognosis and resistance to chemotherapeutic agents. The objectives of this paper is to explore the effectiveness of double-stranded short inhibitory RNAs （siRNA） targeting Her-2/neu oncogene on the drug sensitivity of Her-2/neu-overexpressing lung adenocarcinoma cells. Methods： Lung adenocarcinoma cell line calu-3 was transfected with siRNAs formulated LipofectAMINE 2000, and Her-2/neu protein and P-gp were determined by flow cytometry （FCM）. The chemosensitivity of transfected cells to cisplatin （CDDP） was measured by MTT. Cell apoptosis detection kit （Annexin V method） was used to examine the drug induced apoptosis rate. Results： siRNA targeting Her-2/neu greatly reduced the cell surface expression of Her-2/neu protein and had no effect on P-gp. Consequently the inhibitory rate of CDDP in combination with siRNA targeting Her-2/neu was （67.1±2.3）%, while the inhibitory rates were （48.1±3.5）%, （46.3±5.9）% and （50.2±2.9）% in untreated control, empty vector and unrelated siRNA groups, respectively. The FCM results showed that the apoptosis rate of cells treated with CDDP combined with siRNAs-Her-2/neu was elevated when compared with unrelated siRNA group and empty vector group. Conclusion： Sequence specific siRNA targeting Her-2/neu was capable of enhancing the chemosensitivity of calu-3 cell to cisplatin.
文摘OBJECTIVE Various studies examining the relationship be-tween HER-2 over-expression and the response to chemotherapy and clinical outcome in patients with osteosarcoma have yielded inconclusive results.The purpose of the current study was to evaluate the relation of HER-2 status with the response to chemo-therapy and clinical outcome in osteosarcoma.METHODS We conducted a meta-analysis of 6 studies that evaluated the correlation between HER-2 status and histologic response to chemotherapy and 2-year survival.Data were syn-thesized in summary receiver operating characteristic curves and with summary likelihood ratios(LRs) and relative risk.RESULTS The quantitative synthesis showed that HER-2 status is not a prognostic factor for the response to chemotherapy.The positive LR was 1.27(95% conf idence interval,0.91～1.77),and the negative LR was 0.68(95% confidence interval,0.38～1.22).There was no significant between-study heterogeneity.HER2-positive status tended to be associated with a worse 2-year survival,but the overall results were not formally statistically signif icant.CONCLUSION HER-2 status is not associated with the histo-logic response to chemotherapy in patients with osteosarcoma,whereas HER-2 positive patients may be associated with decreased survival.
文摘目的探讨用荧光原位杂交(fluorescent in situ hybridization,FISH)方法检测乳腺癌HER-2/neu基因表达的临床意义。方法应用FISH法对2008年1月至2008年7月在首都医科大学附属北京天坛医院就诊的33例女性新发乳腺癌患者进行HER-2/neu基因检测,分析基因表达程度与临床病理特征之间的关系,比较基因和免疫组化(IHC)法蛋白表达的差别。结果33位受试者中HER-2/neu基因过表达率为39.4%,其过表达与肿瘤大小、绝经与否、临床分期之间差异无统计学意义(P>0.05)。该基因在有腋淋巴结转移组显著高于无淋巴结转移组(P<0.05),ER阴性组高于ER阳性组,差异有统计学意义(P<0.01)。PR阴性组与阳性组间差异无统计学意义。P53基因阳性组显著高于阴性组(P<0.05)。HER-2/neu基因过表达者11例为免疫组化HER-2蛋白强阳性病例;2例为中度阳性病例。结论FISH技术可稳定检测乳腺癌中HER-2/neu基因的表达程度,其过表达与绝经与否、肿瘤大小、临床分期无关,与腋淋巴结转移和P53基因表达成正相关,与ER呈密切负相关。HER-2蛋白高强度表达(3+)与基因扩增有极好的一致性,而中等强度表达(2+)必须进一步行FISH法基因检测。
